Tao Xie, MD, PhD, specializes in the diagnosis and treatment of various movement disorders, including Parkinson's disease, progressive supranuclear palsy (PSP), multiple system atrophy (MSA), cortical basal ganglionic degeneration (CBGD), Huntington's disease (HD) and chorea, tremor, dystonia, hemifacial spasm, blepharospasm, tics, and Tourette syndrome. He uses medications, botulinum toxin injection and deep brain stimulation surgery for treatment of these neurological conditions.
In his clinical research, Dr. Xie studies the effectiveness of deep brain stimulation for the treatment of various movement disorders. He is also actively involved in clinical trials and research in Parkinson’s disease, PSP, MSA and tremor, and also the role of the DatScan in movement disorders.
Dr. Xie is a physician in the University of Chicago Center for Parkinson's Disease and Movement Disorders. Dedicated as a Center for Advanced Research by the American Parkinson Disease Association, this multidisciplinary center combines clinical expertise with state-of-the-art therapies and groundbreaking research.
Columbia University Medical Center
NY
Fellowship - Movement Disorders
Emory University School of Medicine
GA
Residency - Neurology
Emory University School of Medicine
GA
Internship - Medicine
Johns Hopkins School of Medicine
MD
Research - Neurology
The University of Hong Kong
Ph.D. - Parkinson's Disease
Zhejiang University School of Medicine
China
MD
Utility of Progression Rate Since Symptom Onset in Predicting Subsequent Survival in Progressive Supranuclear Palsy.
Utility of Progression Rate Since Symptom Onset in Predicting Subsequent Survival in Progressive Supranuclear Palsy. Mov Disord. 2026 Jan; 41(1):277-278.
PMID: 41243800
Comments on "Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets".
Comments on "Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets". Mov Disord. 2025 Dec; 40(12):2852-2853.
PMID: 41174991
Healthcare access and utilization of deep brain stimulation and supplementary care in black and white patients with Parkinson's disease.
Healthcare access and utilization of deep brain stimulation and supplementary care in black and white patients with Parkinson's disease. Parkinsonism Relat Disord. 2025 Nov; 140:108057.
PMID: 40986940
Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.
Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy. Mov Disord. 2025 Nov; 40(11):2517-2530.
PMID: 40884249
Multiple System Atrophy.
Multiple System Atrophy. Continuum (Minneap Minn). 2025 08; 31(4):1000-1022.
PMID: 40748131
Bedside Assessment of Downgaze Limit by Amplitude.
Bedside Assessment of Downgaze Limit by Amplitude. Mov Disord Clin Pract. 2025 Dec; 12(12):2224-2231.
PMID: 40641209
Effect of dopaminergic medications on Montreal Cognitive Assessment in Parkinson's disease patients.
Effect of dopaminergic medications on Montreal Cognitive Assessment in Parkinson's disease patients. Parkinsonism Relat Disord. 2025 Sep; 138:107951.
PMID: 40651129
Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome.
Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome. Alzheimers Dement. 2025 07; 21(7):e70485.
PMID: 40684253
Automated Imaging Differentiation for Parkinsonism.
Automated Imaging Differentiation for Parkinsonism. JAMA Neurol. 2025 May 01; 82(5):495-505.
PMID: 40094699
The LRRK2 p.L1795F variant causes Parkinson's disease in the European population.
The LRRK2 p.L1795F variant causes Parkinson's disease in the European population. NPJ Parkinsons Dis. 2025 Mar 25; 11(1):58.
PMID: 40133296